Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58460Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 蘇璧伶(Bi-Ling Su) | |
| dc.contributor.author | Tsung-Fei Wen | en |
| dc.contributor.author | 溫琮斐 | zh_TW |
| dc.date.accessioned | 2021-06-16T08:15:56Z | - |
| dc.date.available | 2014-02-26 | |
| dc.date.copyright | 2014-02-26 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-02-12 | |
| dc.identifier.citation | Addie, D.D., Dennis, J.M., Toth, S., Callanan, J.J., Reid,
S., Jarrett, O., 2000. Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus. Vet Rec 146, 419-424. Anderson, M.M., Lauring, A.S., Burns, C.C., Overbaugh, J., 2000. Identification of a cellular cofactor required for infection by feline leukemia virus. Science 287, 1828- 1830. Barnett, A.L., Wensel, D.L., Li, W., Fass, D., Cunningham, J.M., 2003. Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus. J Virol 77, 2717-2729. Barr, M.C., 1996. FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results. Semin Vet Med Surg (Small Anim) 11, 144-153. Benveniste, R.E., Sherr, C.J., Todaro, G.J., 1975. Evolution of type C viral genes: origin of feline leukemia virus. Science 190, 886-888. Cotter, S.M., 1979. Anemia associated with feline leukemia virus infection. J Am Vet Med Assoc 175, 1191-1194. Cotter, S.M., 1991. Management of healthy feline leukemia virus-positive cats. J Am Vet Med Assoc 199, 1470-1473. Cotter, S.M., Hardy, W.D., Jr., Essex, M., 1975. Association of feline leukemia virus with lymphosarcoma and other disorders in the cat. J Am Vet Med Assoc 166, 449-454. Cotter, S.M., 1998. Feline viral neoplasia, pp 71 - 84. In Greene CE (ed), Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia, PA. de Mari, K., Maynard, L., Sanquer, A., Lebreux, B., Eun, H.M., 2004. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J Vet Intern Med 18, 477-482. Domenech, A., Miro, G., Collado, V.M., Ballesteros, N., Sanjose, L., Escolar, E., Martin, S., Gomez-Lucia, E., 2011. Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet Immunol Immunopathol 143, 301-306. Englert, T., Lutz, H., Sauter-Louis, C., Hartmann, K., 2012. Survey of the feline leukemia virus infection status of cats in Southern Germany. J Feline Med Surg 14, 392-398. Flynn, J.N., Dunham, S.P., Watson, V., Jarrett, O., 2002. Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. J Virol 76, 2306-2315. Francis, D.P., Essex, M., Hardy, W.D., Jr., 1977. Excretion of feline leukaemia virus by naturally infected pet cats. Nature 269, 252-254. Francis, D.P., Essex, M., Jakowski, R.M., Cotter, S.M., Lerer, T.J., Hardy, W.D., Jr., 1980. Increased risk for lymphoma and glomerulonephritis in a closed population of cats exposed to feline leukemia virus. Am J Epidemiol 111, 337-346. Gleich, S., Hartmann, K., 2009. Hematology and serum biochemistry of feline immunodeficiency virus-infected and feline leukemia virus-infected cats. J Vet Intern Med 23, 552-558. Gleich, S.E., Krieger, S., Hartmann, K., 2009. Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany. J Feline Med Surg 11, 985-992. Gomes-Keller, M.A., Gonczi, E., Grenacher, B., Tandon, R., Hofman-Lehmann, R., Lutz, H., 2009. Fecal shedding of infectious feline leukemia virus and its nucleic acids: a transmission potential. Vet Microbiol 134, 208-217. Grant, C.K., Essex, M., Gardner, M.B., Hardy, W.D., Jr., 1980. Natural feline leukemia virus infection and the immune response of cats of different ages. Cancer Res 40, 823-829. Greggs, W.M., Clouser, C.L., Patterson, S.E., Mansky, L.M., 2012. Discovery of drugs that possess activity against feline leukemia virus. J Gen Virol 93, 900-905. Hartmann, K., 2011. Clinical aspects of feline immunodeficiency and feline leukemia virus infection. Vet Immunol Immunopathol 143, 190-201. Hartmann, K., 2012. Clinical aspects of feline retroviruses: a review. Viruses 4, 2684-2710. Hayes, K.A., Rojko, J.L., Mathes, L.E., 1992. Incidence of localized feline leukemia virus infection in cats. Am J Vet Res 53, 604-607. Hofmann-Lehmann, R., Huder, J.B., Gruber, S., Boretti, F., Sigrist, B., Lutz, H., 2001. Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats. J Gen Virol 82, 1589-1596. Hoover, E.A., Mullins, J.I., 1991. Feline leukemia virus infection and diseases. J Am Vet Med Assoc 199, 1287-1297. Hoover, E.A., Olsen, R.G., Hardy, W.D., Jr., Schaller, J.P., Mathes, L.E., 1976. Feline leukemia virus infection: age- related variation in response of cats to experimental infection. J Natl Cancer Inst 57, 365-369. Hosie, M.J., Robertson, C., Jarrett, O., 1989. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom. Vet Rec 125, 293-297. Jameson, P., Essex, M., 1983. Inhibition of feline leukemia virus replication by human leukocyte interferon. Antiviral Res 3, 115-120. Jarrett, O., 1995. Detection of FeLV antigen. Vet Rec 137, 127. Jarrett, O., Golder, M.C., Stewart, M.F., 1982. Detection of transient and persistent feline leukaemia virus infections. Vet Rec 110, 225-228. Jarrett, O., Russell, P.H., 1978. Differential growth and transmission in cats of feline leukaemia viruses of subgroups A and B. Int J Cancer 21, 466-472. Jarrett, W.F., Crawford, E.M., Martin, W.B., Davie, F., 1964. A Virus-Like Particle Associated with Leukemia (Lymphosarcoma). Nature 202, 567-569. Kohn, B., Weingart, C., Eckmann, V., Ottenjann, M., Leibold, W., 2006. Primary immune-mediated hemolytic anemia in 19 cats: diagnosis, therapy, and outcome (1998-2004). J Vet Intern Med 20, 159-166. Lafrado, L.J., 1994. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study. J Am Vet Med Assoc 204, 914-917. Langhammer, S., Hubner, J., Kurth, R., Denner, J., 2006. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Immunology 117, 229-237. Lauring, A.S., Cheng, H.H., Eiden, M.V., Overbaugh, J., 2002. Genetic and biochemical analyses of receptor and cofactor determinants for T-cell-tropic feline leukemia virus infection. J Virol 76, 8069-8078. Lee, I.T., Levy, J.K., Gorman, S.P., Crawford, P.C., Slater, M.R., 2002. Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats. J Am Vet Med Assoc 220, 620- 622. Legendre, A.M., Hawks, D.M., Sebring, R., Rohrbach, B., Chavez, L., Chu, H.J., Acree, W.M., 1991. Comparison of the efficacy of three commercial feline leukemia virus vaccines in a natural challenge exposure. J Am Vet Med Assoc 199, 1456-1462. Levy, J., Richards, J., Edwards, D., Elston, T., Hartmann, K., Rodan, I., Thayer, V., Tompkins, M., Wolf, A., 2003. 2001 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on feline retrovirus testing and management. J Feline Med Surg 5, 3-10. Levy, J.K., Scott, H.M., Lachtara, J.L., Crawford, P.C., 2006. Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity. J Am Vet Med Assoc 228, 371-376. Lin, J.A., Cheng, M.C., Inoshima, Y., Tomonaga, K., Miyazawa, T., Tohya, Y., Toh, K., Lu, Y.S., Mikami, T., 1995. Seroepidemiological survey of feline retrovirus infections in cats in Taiwan in 1993 and 1994. J Vet Med Sci 57, 161-163. Little, S., 2011. A review of feline leukemia virus and feline immunodeficiency virus seroprevalence in cats in Canada. Vet Immunol Immunopathol 143, 243-245. Little, S.E., 2005. Feline immunodeficiency virus testing in stray, feral, and client-owned cats of Ottawa. Can Vet J 46, 898-901. Major, A., Cattori, V., Boenzli, E., Riond, B., Ossent, P., Meli, M.L., Hofmann-Lehmann, R., Lutz, H., 2010. Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection. Vet Res 41, 17. Middleton, D.J., Watson, A.D., 1985. Glucose intolerance in cats given short-term therapies of prednisolone and megestrol acetate. Am J Vet Res 46, 2623-2625. Miyazawa, T., Jarrett, O., 1997. Feline leukaemia virus proviral DNA detected by polymerase chain reaction in antigenaemic but non-viraemic ('discordant') cats. Arch Virol 142, 323-332. Moser, M., Burns, C.C., Boomer, S., Overbaugh, J., 1998. The host range and interference properties of two closely related feline leukemia variants suggest that they use distinct receptors. Virology 242, 366-377. Nishigaki, K., Okuda, M., Endo, Y., Watari, T., Tsujimoto, H., Hasegawa, A., 1997. Structure and function of the long terminal repeats of feline leukemia viruses derived from naturally occurring acute myeloid leukemias in cats. J Virol 71, 9823-9827. Pacitti, A.M., Jarrett, O., 1985. Duration of the latent state in feline leukaemia virus infections. Vet Rec 117, 472-474. Pattullo, K., 2008. Acute bullous keratopathy in a domestic shorthair. Can Vet J 49, 187-189. Quackenbush, S.L., Dean, G.A., Mullins, J.I., Hoover, E.A., 1996. Analysis of FeLV-FAIDS provirus burden and productive infection in lymphocyte subsets in vivo. Virology 223, 1-9. Quigley, J.G., Burns, C.C., Anderson, M.M., Lynch, E.D., Sabo, K.M., Overbaugh, J., Abkowitz, J.L., 2000. Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia. Blood 95, 1093-1099. Reinacher, M., 1989. Diseases associated with spontaneous feline leukemia virus (FeLV) infection in cats. Vet Immunol Immunopathol 21, 85-95. Rogers, R., Merigan, T.C., Hardy, W.D., Jr., Old, L.J., Kassel, R., 1972. Cat interferon inhibits feline leukaemia virus infection in cell culture. Nat New Biol 237, 270- 271. Rojko, J.L., Hoover, E.A., Quackenbush, S.L., Olsen, R.G., 1982. Reactivation of latent feline leukaemia virus infection. Nature 298, 385-388. Sapian, N.A., Arshad, S.S., Dhaliwal, G.K., Bande, F., 2011. Serological Prevalence of FeLV and FIV in Cats in Peninsular Malaysia. Proc, 78-82 Sarma, P.S., Log, T., 1971. Viral interference in feline leukemia-sarcoma complex. Virology 44, 352-358. Sheets, R.L., Pandey, R., Jen, W.C., Roy-Burman, P., 1993. Recombinant feline leukemia virus genes detected in naturally occurring feline lymphosarcomas. J Virol 67, 3118-3125. Shelton, G.H., Grant, C.K., Cotter, S.M., Gardner, M.B., Hardy, W.D., Jr., DiGiacomo, R.F., 1990. Feline immunodeficiency virus and feline leukemia virus infections and their relationships to lymphoid malignancies in cats: a retrospective study (1968-1988). J Acquir Immune Defic Syndr 3, 623-630. Stuetzer, B., Brunner, K., Lutz, H., Hartmann, K., 2013. A trial with 3'-azido-2',3'-dideoxythymidine and human interferon-alpha in cats naturally infected with feline leukaemia virus. J Feline Med Surg 15, 667-671. Torres, A.N., O'Halloran, K.P., Larson, L.J., Schultz, R.D., Hoover, E.A., 2010. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet Immunol Immunopathol 134, 122-131. Vobis, M., D'Haese, J., Mehlhorn, H., Mencke, N., 2003. Evidence of horizontal transmission of feline leukemia virus by the cat flea ( Ctenocephalides felis). Parasitol Res 91, 467-470. Willett, B.J., Hosie, M.J., 2013. Feline leukaemia virus: half a century since its discovery. Vet J 195, 16-23. Zeidner, N.S., Myles, M.H., Mathiason-DuBard, C.K., Dreitz, M.J., Mullins, J.I., Hoover, E.A., 1990. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 34, 1749-1756. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58460 | - |
| dc.description.abstract | 貓白血病毒 (Feline leukemia virus, FeLV)及貓免疫缺陷病毒 (feline immunodeficiency virus, FIV)皆為造成貓隻疾病之反轉錄病毒。其中FeLV較具有致病性，亦較其他種病原更容易發展出多樣性的臨床呈像。為了解台灣地區貓反轉錄病毒在不同生活型態貓中的感染率，本研究首先調查2005至2006年FeLV，發現在流浪貓及家貓感染率分別為3% (5/161)及1.6% (3/188)，而FIV則分別為14% (23/161)及7.9% (15/188)。其中43隻感染FeLV的貓隻發生率最高的相關疾病為貧血 (26/43, 60.5%)、其次為腫瘤 (16/43, 37.2%)。而26隻出現貧血的患貓中，有17隻 (17/26, 65.4%)罹患免疫性溶血性貧血，顯示在貓白血病相關之貧血疾病中，免疫性溶血性貧血也可能是造成貧血的原因之一。為評估合併使用類固醇及人類和成干擾素治療FeLV誘發免疫性溶血性貧血之成效，本研究收集17隻年齡中位數為3歲 (0.8-7歲)之貓白血病p27 Ag陽性、同時發生自體凝集或球狀紅血球增多症診斷為免疫性溶血性貧血之患貓，將其分成兩組。其中10隻貓合併使用類固醇 (0.5-8 mg/kg/day)和人類重組干擾素 (2.5x105-1x106 IU/kg, SC SID-Q2D)治療為group 1，另外7隻貓單獨使用類固醇 (0.5-2 mg/kg/day)治療為group 2。Group 1貓隻於第14天時之血紅素與血容比均顯著高於group 2，治療組的存活時間亦顯著長於控制組 (p<0.05)。治療組中最長存活期為大於1600天。本研究中13隻長期使用類固醇控制貓白血病相關免疫性溶血性貧血之患貓中， 10隻貓出現高血糖，其中6隻貓更出現需以胰島素控制之糖尿病及2隻患貓發生角膜病變。總結，台灣地區貓白血病及貓愛滋病之盛行率在流浪貓約為家貓之兩倍。本研究為首篇針對貓白血病誘發免疫性溶血性貧血患貓合併使用人類重組干擾素α與類固醇治療之研究。結果顯示治療組在血液學檢查結果及存活期都顯著優於控制組，除了長時間使用高劑量類固醇所造成的高血糖、糖尿病與角膜病變之外，並未出現與人類重組干擾素-α相關之副作用。本研究結果提供臨床上貓白血病相關免疫性溶血性貧血時一個新的治療選擇。 | zh_TW |
| dc.description.abstract | Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are retroviruses with global impact on the health of domestic cats. This study was conducted to determine prevalence of strayed and client-owned cats for retrovirus
infection in Taiwan by examination of FIV antibodies or FeLV antigen. Immune mediated anemia and tumor are the most common diseases caused by FeLV in this study. 17 cats, the medium of age was 3 years old (range from 0.8 to 7 years), were confirmed with feline leukemia virus infection and diagnosed with immune mediated hemolytic anemia (IMHA) by autoagglutination and spherocytosis. We separated them into two groups. Group 1 (n=10) was treated with a combination of prednisolone (range: 0.5-8 mg/kg) orally per day and injected subcutaneously with human interferon-α-2a (Roferon-AR, range: 2.5x105-1x106IU/kg) every days initially and reduced the frequency after remission of anemia. Group 2 (n=7) was treated with prednisolone orally (range: 0.5-2 mg/kg) per day only. Since then RBC and PCV are both statistic significant higher in group 1 than group 2 in the 14th day of treatment. Moreover, the survival time of group 1 is significantly longer than group 2. The longest survival time in group 1 is 1600 days (still alive). 10 (10/13) cats developed hyperglycemia after long-term prednisolone administration (>30 days), in which, 6 (6/13) cats developed steroid-induced diabetes mellitus and were controlled under insulin injection thereafter. 2 (2/13) cats developed keratopathy bullae as well. In conclusion, prevalence of retrovirus infection is higher in strayed cats than in client-owned cats in Taiwan. The combination of prednisolone and interferon-α showed an effective therapeutic strategy in control of FeLV induced IMHA anemic patients. Although hyperglycemia, diabetes mellitus and keratopathy bullae appeared during the treatment, it’s still provided a good alternative choice in treating FeLV induced IMHA. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T08:15:56Z (GMT). No. of bitstreams: 1 ntu-103-R00643007-1.pdf: 1091186 bytes, checksum: 58c3561a46611f279235c126b802c2be (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 摘要…………………………………………………………………………………………………………………………i
Abstract…………………………………………………………………………………………………………iii 目錄…………………………………………………………………………………………………………………………v 表次……………………………………………………………………………………………………………………viii 圖次………………………………………………………………………………………………………………………ix 附錄…………………………………………………………………………………………………………………………x 第一章、 文獻探討……………………………………………………………………………………………1 第一節、歷史背景……………………………………………………………………………………1 第二節、貓白血病毒之介紹……………………………………………………………………1 2.1 病毒特性………………………………………………………………………1 2.2 病毒分類………………………………………………………………………2 2.3 流行病學………………………………………………………………………3 2.4 傳染途徑………………………………………………………………………3 2.5 致病機轉………………………………………………………………………5 第三節、臨床特徵………………………………………………………………………………………6 第四節、診斷………………………………………………………………………………………………8 4.1 臨床病理學……………………………………………………………………8 4.2 病毒分離………………………………………………………………………8 4.3 酵素聯結免疫吸附試驗………………………………………………8 4.4 核酸檢驗…………………………………………………………………………9 第五節、預防與治療……………………………………………………………………………………9 5.1 貓白血病的控制……………………………………………………………10 5.2 疫苗接種…………………………………………………………………………10 5.3 FeLV的治療…………………………………………………………………11 第二章、 序言………………………………………………………………………………………………………14 第三章、 材料與方法…………………………………………………………………………………………15 I. 台灣貓白血病毒及貓免疫缺陷病毒感染率之調查……………………15 第一節、 動物來源………………………………………………………………………………………………15 第二節、 檢驗方式………………………………………………………………………………………………15 II. 感染FeLV貓隻與該病毒誘發的疾病之相關性……………………………15 第一節、動物來源………………………………………………………………………………………15 第二節、FeLV p27 Ag陽性貓隻與相關疾病之調查………………………15 第三節、FeLV p27 Ag檢驗與聚合酶鏈鎖反應………………………………16 3.1 DNA 萃取…………………………………………………………………………16 3.2 RNA 萃取……………………………………………………………………………17 3.3 反轉錄反應…………………………………………………………………………17 3.4 巢式多重引子聚合酶鏈鎖反應………………………………………17 3.5 電泳分析……………………………………………………………………………18 III. 類固醇與Human recombinant Interferon-α (rhIFN-α)之藥物合用於FeLV誘發免疫性溶血性貧血患貓治療效果之評估…………………………………18 第一節、動物來源………………………………………………………………………………………18 第二節、治療成效評估………………………………………………………………………………19 第三節、統計分析………………………………………………………………………………………19 第四章、 結果……………………………………………………………………………………………………20 I. FeLV及FIV感染率之調查………………………………………………………………20 II. 感染FeLV貓隻與該病毒誘發的疾病之相關性……………………………20 第一節、動物來源…………………………………………………………………………………………20 第二節、FeLV陽性與其所誘發之疾病或同時罹患的疾病之分析………20 第三節、FeLV p27 Ag檢驗與聚合酶鏈鎖反應結果之關係………………21 III. FeLV誘發免疫性溶血性貧血貓之不同治療組合評估…………………………22 第一節、動物來源……………………………………………………………………………………………22 第二節、血液檢查、治療成效與長期使用類固醇之副作用…………………22 第五章、 討論…………………………………………………………………………………………………………26 附表 ………………………………………………………………………………………………………………………………33 附圖 ………………………………………………………………………………………………………………………………48 附錄 ………………………………………………………………………………………………………………………………49 第六章、 References…………………………………………………………………………………………51 表次 Table 1. FeLV and FIV infection exist in domestic cats worldwide…………………………………………………………………………………………………………………………33 Table 2. Basal finding of 42 cats with FeLV infection…… 37 Table 3. Signalment of FeLV infected cats……………………………………39 Table 4. The correlation of p27 Ag and PCR results………………40 Table 5. The correlation of p27 Ag and RT-PCR results………41 Table 6. Signalment of the cats with FeLV induced IMHA……42 Table 7. Therapeutic strategies of group1 and group2…………43 Table 8. Severity of anemia of 17 FeLV induced IMHA cats at presentation……………………………………………………………………………………………………………………44 Table 9. Serial hematologic findings of 17 FeLV-related IMHA cats during the therapy………………………………………………………………………………………45 Table 10. Serial hematologic findings of 17 FeLV-related IMHA cats during the therapy…………………………………………………………………………46 Table 11. Classification of the cats according to survival time…………………………………………………………………………………………………………………………………………47 圖次 Fig 1. Kaplan-Meier survival curve of cats in group 1 and group 2……………………………………………………………………………………………………………………………48 附錄 Appendix 1. The sequence of primers used in the detection of Feline leukemia virus cDNA………………………………………………………………………………49 Appendix 2. Results of nested PCR of FeLV infected cats………50 | |
| dc.language.iso | zh-TW | |
| dc.subject | 貓免疫缺陷病毒 | zh_TW |
| dc.subject | 人類重組干擾素α | zh_TW |
| dc.subject | 類固醇 | zh_TW |
| dc.subject | 糖尿病 | zh_TW |
| dc.subject | 貓白血病毒 | zh_TW |
| dc.subject | 貓免疫性溶血性貧血 | zh_TW |
| dc.subject | Prednisolone | en |
| dc.subject | Recombinant human recombinant interferon-α | en |
| dc.subject | Feline immune mediated hemolytic anemia | en |
| dc.subject | Feline immunodificiency virus | en |
| dc.subject | Feline leukemia virus | en |
| dc.subject | Diabetes mellitus | en |
| dc.title | 貓白血病於
台灣盛行率之調查與藥物組合(類固醇與人類合成干擾素α)於此病毒誘發免疫性溶血性貧血貓治療效果之評估 | zh_TW |
| dc.title | Feline Leukemia Virus:
I. Evaluation of prevalence in Taiwan II. Therapeutic efficacy of a novel combination of prednisolone and human recombinant interferon-α in FeLV induced immune mediated hemolytic anemic cats | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 闕玲玲(Ling-Ling Chueh) | |
| dc.contributor.oralexamcommittee | 王金和(Ching-Ho Wang),林昭男(Chao-Nan Lin) | |
| dc.subject.keyword | 貓白血病毒,貓免疫缺陷病毒,貓免疫性溶血性貧血,人類重組干擾素α,類固醇,糖尿病, | zh_TW |
| dc.subject.keyword | Feline leukemia virus,Feline immunodificiency virus,Feline immune mediated hemolytic anemia,Recombinant human recombinant interferon-α,Prednisolone,Diabetes mellitus, | en |
| dc.relation.page | 55 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-02-12 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
| Appears in Collections: | 臨床動物醫學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-103-1.pdf Restricted Access | 1.07 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.